NCT03747133

SABR for Renal Tumors

Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.

Conditions

• Renal Tumor

Interventions

Type	Name	Description
RADIATION	Stereotactic Ablative Radiotherapy	Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.

Timeline

• Start date: 2018-11-01
• Primary completion: 2027-11-01
• Completion: 2027-11-01
• First posted: 2018-11-20
• Last updated: 2025-02-20

Locations

2 sites across 1 country: Canada